Dr. Arthi Kanthasamy studies neuroinflammation with an emphasis on the novel neuroinflammatory mechanisms underlying Parkinson’s disease (PD), including autophagy, oxidative stress and exosome trafficking machinery. She has supported her research endeavors by garnering funding from both NIH- and DOD-funded programs over the last two decades. Her lab’s translational efforts include the identification of immunotherapies, small molecule inhibitors and antioxidant therapeutics aimed at subcellular organelles, in addition to studying novel cell signaling mediators in diverse preclinical models of PD to pave the way for clinical trials as well as preclinical testing. She has authored more than 100 peer-reviewed papers and has undertaken multiple multidisciplinary research collaborations to unravel the cellular mechanisms underlying PD-like pathology. She has also mentored numerous graduate students and postdoctoral fellows.
Associated Grants
-
Targeting Colony-stimulating Factor 1 Receptor (CSF1R) to Modify Disease Progression in Preclinical Experimental Models of Parkinson’s Disease
2022
-
Pharmacological Targeting of Inflammation to Modify Disease Progression in Pre-clinical Models of Parkinson’s Disease
2021